{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:17:45Z","timestamp":1789690665814,"version":"4.0.1"},"reference-count":58,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>G\u2010EPOSS is a prospective, non\u2010interventional, German multicentre study of patients with moderate\u2010to\u2010severe plaque psoriasis receiving guselkumab, a therapeutic monoclonal antibody targeting interleukin\u201023, in a real\u2010world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The objective of the study was to evaluate the effectiveness and safety of guselkumab, including its impact on skin, health\u2010related quality of life (HRQoL), sexuality, and perceived stigmatization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients (\u226518\u2009years old) received guselkumab per routine clinical practice. The primary endpoint was the proportion of patients achieving absolute Psoriasis Area and Severity Index (PASI) \u2264 3 at Week (W)28. Secondary endpoint assessments over 28\u2009weeks included the Nail Psoriasis Severity Index (NAPSI), anogenital Physician's Global Assessment (aPGA), and Dermatology Life Quality Index (DLQI). Sexuality and perceived stigmatization were assessed by patients using the Relationship and Sexuality Scale (RSS) and Perceived Stigmatization Questionnaire (PSQ), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 293 patients were included in the evaluable set population. Mean age and disease duration were 45.6 and 17.6\u2009years, respectively. At baseline, mean PASI, aPGA and DLQI scores were 15.3, 2.7 and 11.3, respectively. In total, 25.9% of patients had received a prior biologic. Overall, 83.0% of patients achieved PASI\u2009\u2264\u20093, and 56.2%\/35.1% achieved PASI\u2009\u2264\u20091\/PASI\u2009=\u20090, respectively, at W28. Among those with NAPSI\u2009\u2265\u20091 and aPGA\u2009\u2265\u20091 at baseline, NAPSI\u2009=\u20090 and aPGA\u2009=\u20090 were achieved by 39.2% and 61.1% of patients, respectively, and 61.4% of patients achieved DLQI 0\u20131 at W28. Improvements were observed over 28\u2009weeks across individual items of the DLQI, RSS and PSQ, indicating improved HRQoL and sex life, and decreased perceived stigmatization. Based on DLQI Question (Q)9, 53.6% of patients experienced sexual difficulties at baseline, which decreased to 12.1% at W28. DLQI Q9 responses were consistent with RSS item responses, highlighting DLQI Q9 as a sentinel for sexual impairment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Guselkumab improved overall skin symptoms and HRQoL in patients with psoriasis and decreased sexual impairment and perceived stigmatization. No new safety signals were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study code<\/jats:title>\n                    <jats:p>CNTO1959PSO4008.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.19927","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T06:14:40Z","timestamp":1712816080000},"page":"15-26","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effectiveness, safety and impact of guselkumab on sexuality and perceived stigmatization in patients with psoriasis in routine clinical practice: Week 28 results from the prospective German multicentre\n                    <scp>G\u2010EPOSS<\/scp>\n                    study"],"prefix":"10.1111","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6667-7757","authenticated-orcid":false,"given":"S.","family":"Gerdes","sequence":"first","affiliation":[{"name":"Psoriasis Center Kiel, Department of Dermatology University Medical Center Schleswig\u2010Holstein  Kiel Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ostendorf","sequence":"additional","affiliation":[{"name":"ZENTderma  M\u00f6nchengladbach Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"S\u00fc\u00df","sequence":"additional","affiliation":[{"name":"Dermatology Practice Dr. med. Anke S\u00fc\u00df  Wittlich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Schadeck","sequence":"additional","affiliation":[{"name":"Dermatology Practice Tobias Schadeck  Bogen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Taut","sequence":"additional","affiliation":[{"name":"Taut Science and Service GmbH  Konstanz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Makuc","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag GmbH  Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Scharfenberger","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag GmbH  Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag GmbH  Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Trenkler","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag GmbH  Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Behrens","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag GmbH  Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Joks","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag Pty Ltd  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tabori","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag GmbH  Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Mortazawi","sequence":"additional","affiliation":[{"name":"Dermatology Practice Dariusch Mortazawi  Remscheid Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,11]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.039"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12233"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03705.x"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-017-0204-3"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10280.x"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2011.01261.x"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-017-1065-z"},{"issue":"1","key":"e_1_2_10_10_1","article-title":"Cumulative life course impairment: paving the way to an extended life course approach in dermatology","volume":"164","author":"Linder D","year":"2011","journal-title":"Br J Dermatol"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17348"},{"key":"e_1_2_10_12_1","unstructured":"World Health Assembly.Sixty\u2010seventh World Health Assembly WHA67.9: psoriasis.2014. Available from:https:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA67\/A67_R9\u2010en.pdf. Accessed 30 September 2023."},{"key":"e_1_2_10_13_1","unstructured":"World Health Organization.Global report on psoriasis.2016. Available from:https:\/\/www.who.int\/publications\/i\/item\/9789241565189. Accessed 30 September 2023."},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20153254"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16076"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12895-020-00099-7"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17147"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000338858"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1453125"},{"key":"e_1_2_10_20_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235091","article-title":"Sex\u2010related impairment and patient needs\/benefits in anogenital psoriasis: difficult\u2010to\u2010communicate topics and their impact on patient\u2010centred care","volume":"15","author":"Silva N","year":"2020","journal-title":"PLoS ONE"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21827"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17829"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1159\/000510654"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(89)70007-4"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v101.565"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000448122"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0800-7"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16511"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072170"},{"key":"e_1_2_10_30_1","first-page":"406","article-title":"Real\u2010world effectiveness and safety of guselkumab for the treatment of psoriasis: a 6\u2010month prospective study in a series of psoriatic patients","volume":"25","author":"Malara G","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475420932514"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1800577"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13344"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14798"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13964"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16128"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15750"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18218"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1067\/S0190-9622(03)00910-1"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.865009"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.391"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.10.024"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-71"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.02.1127"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1037\/1040-3590.18.1.106"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.burns.2016.01.001"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049822"},{"key":"e_1_2_10_51_1","first-page":"48","article-title":"German psoriasis registry PsoBest: objectives, methodology and baseline data","volume":"12","author":"Augustin M","year":"2014","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31773-8"},{"key":"e_1_2_10_53_1","unstructured":"K\u00f6rberA JoksG WegnerS KrampeS Tha\u00e7iD.Sexual impairment in psoriasis patients with moderate to severe disease: post\u2010hoc analysis on results from the POLARIS trial across Germany. Poster presented at Deutschen Dermatologische Gesellschaft (DDG) congress Berlin Germany 1\u20134 May 2019; poster 2497."},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17403"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00622-7"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1177\/2475530318781339"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16568"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14684"},{"key":"e_1_2_10_59_1","unstructured":"KorgeB AsadullahK SticherlingM HoffmannM MortazawiD Kr\u00fcgerN et\u00a0al.High levels of patient and physician satisfaction and improved work productivity with guselkumab through 2\u2009years in patients with moderate\u2010to\u2010severe plaque psoriasis: results from the real\u2010world PERSIST study. Abstract presented at 31st European Academy of Dermatology and Venerology congress Milan Italy; 7\u201310 September 2022; abstract 1144."}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.19927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T03:32:16Z","timestamp":1741750336000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.19927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,11]]},"references-count":58,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1111\/jdv.19927"],"URL":"https:\/\/doi.org\/10.1111\/jdv.19927","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,11]]},"assertion":[{"value":"2023-10-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}